May 13 |
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
|
May 8 |
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
|
Apr 30 |
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
|
Apr 17 |
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
|
Apr 10 |
Recce Pharmaceuticals Provides Business Update
|
Apr 10 |
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
|
Apr 4 |
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
|
Mar 22 |
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
|
Mar 19 |
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
|
Mar 14 |
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
|